Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy - Preliminary evidence

International Journal of Biological Markers

Volumn 28, Issue 2, 2013, Pages 182-186

  Lin, Pei Ching ^a   Lin, Hung Hsin ^b   Lin, Jen Kou ^b   Lin, Chun Chi ^b   Yang, Shung Haur ^b   Li, Anna Fen Yau ^b   Chen, Wei Shone ^b   Chang, Shih Ching ^b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

5 FU; ABCG2; Colorectal cancer; Metastasis; Oxaliplatin; Prognosis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FLUOROURACIL; OXALIPLATIN;

ARTICLE; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RADIODENSITOMETRY; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PARAFFIN EMBEDDING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879723603     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000004     Document Type: Article

References (22)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
2. de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, Andre T; GERCOR French Oncology Research Group. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer 2011; 10: 218-26.
3. Mahteme H, Pahlman L. Good colorectal cancer surgery. Tech Coloproctol 2005; 9: 1-7.
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
5. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
6. Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam Clin Pharmacol 2004; 18: 413-22.
7. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 2011; 17: 89-95.
8. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
10. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-59.
11. Candeil L, Gourdier I, Peyron D, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan- treated metastases. Int J Cancer 2004; 109: 848-54.
12. Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009; 78: 1366-73.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
14. Diestra JE, Scheffer GL, Català I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198: 213-9.
15. Larbcharoensub N, Sornmayura P, Sirachainan E, Wilasrusmee C, Wanmoung H, Janvilisri T. Prognostic valueof ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. Histopathology 2011; 59: 235-46.
16. Oh PS, Patel VB, Sanders MA, et al. Schlafen-3 decreases cancer stem cell marker expression and autocrine/ juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2011; 301: G347-55.
17. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
18. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45: 872-7.
19. Gupta N, Martin PM, Miyauchi S, et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006; 343: 571-7.
20. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F. Effect of ABCG2 on cytotoxicity of platinumdrugs: interference of EGFP. Toxicol In Vitro 2008; 22: 1846-52.
21. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232: 643-5.
22. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpressionof a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.